Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lonsurf Gets EU Nod for Gastric Cancer: Taiho
July 30, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Bayer Files Eylea for Neovascular Glaucoma
July 29, 2019
- Takeda, Meiji to End Copromotion for Rozerem
July 29, 2019
- Pfizer, Takeda Wind Up Enbrel Copromotion
July 29, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Opdivo Posts Mixed Results in 1st-Line NSCLC, Scores Win in I/O-I/O Combo
July 26, 2019
- Sumitomo Dainippon to Invest in US Blood Sample Device Startup
July 26, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
- Novo Files Oral Semaglutide in Japan
July 25, 2019
- Ayumi to Ease Restrictions on Enbrel Biosimilar Use as Product Boost Progresses
July 24, 2019
- HIF-PH Inhibitor Vadadustat Submitted in Japan: Mitsubishi Tanabe
July 24, 2019
- Lenvima/Keytruda Gets FDA’s Breakthrough Status for HCC
July 24, 2019
- Dissolving JV with Takeda, PRA Launches Independent CRO Biz in Japan
July 24, 2019
- Boehringer Said to Consider Nixing Allowances for Some Wholesalers, Denies Intention to Narrow Distributors
July 23, 2019
- Lonasen Effective in Adolescent Japanese Schizophrenia Patients: Sumitomo Dainippon
July 23, 2019
- Nichi-Iko Gets Distribution Rights to Chugai’s Ulcerlmin
July 23, 2019
- Shire’s Vonvendi Filed in Japan
July 23, 2019
- Aspen Japan to Take Over Bristol’s Antiarrhythmic Agent
July 23, 2019
- Ono/BMS, Bayer to Develop Opdivo-Stivarga Combo
July 22, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…